Anti-CD47 mAbs could offer clear benefits in the treatment of cardiovascular diseases, however their use as anticancer drugs is likely to encounter the same limitations as bevacizumab, i.e., hypertension, thromboembolism, and tumor recurrence (Gil-Gil et al., 2013). This evidence concerns the gene CD47 and Hypertension.